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and capecitabine monotherapy in terms of incidence of diarrhea, vomiting, sto-
matitis/mucositis. The hand-foot syndrome occurrred in less than 5% in case of 
tegafur. Tegafur (in monotherapy or in combination with calcium folinate) is less 
costly than capecitabine. The difference in costs in favor of tegafur monotherapy 
amounted to € 1,956.97 per 1 patient per 6 months or € 3,778.53 per year; of tegafur + 
calcium folinate - € 2,168.12 and € 4,220.06 per 1 patient per 6 and 12 months, respec-
tively. ConClusions: Tegafur is a cost-saving option compared with capecitabine 
with similar efficacy and safety.
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objeCtives: There is new RCT phase 3 clinical evidence that bendamustin-
rituximab (B-R) is more effective in terms of progression free survival compared 
to the standard of care CHOP-rituximab (CHOP-R) in indolent non-Hodgkin lym-
phoma (iNHL). Based on this RCT, we performed a cost-utility analysis of B-R com-
pared to CHOP-R in the treatment of follicular iNHL (stage III and IV) in the Czech 
Republic. Methods: We developed a life-time Markov cohort model with 28-day 
cycle length and 5 health states, i.e. on treatment, rituximab maintenance (R-M), 
stable disease, progression and death. Additionally, we modeled adverse effects 
of treatment and four sub-states during progression (observation, imunochemo-
therapy, R-M, post R-M). Transition probabilities and utilities were derived from 
published literature. Resource use (costs) was calculated from health care payer’s 
perspective in cooperation with major Czech hemato-oncologic experts. Costs and 
outcomes were discounted by 3.5%. Probabilistic sensitivity analysis (PSA) with 
1000 iterations using a willingness to pay (WTP) threshold equal to 3 times GDP per 
capita (40 100 EUR) in the Czech Republic was performed. Results: Over a life-time 
horizon, B-R compared to CHOP-R brings additional 1.21 QALY (7.47 vs. 6.26) and 1.31 
LYG (9.74 vs. 8.43). The incremental total costs were 1,368 EUR (total life time costs 
for B-R and CHOP-R were 43,080 EUR and 41,712 EUR, respectively). ICERs thus equal 
to 1,133 EUR/QALY and 1,044 EUR/LYG. The results of the PSA show that B-R is cost-
effective in 100% iterations under the WTP threshold; and simultaneously in 99.3% 
iterations is cost-effective while using threshold equal to 7,300 EUR. ConClusions: 
B-R proved that it is a highly cost-effective therapy in patients with follicular iNHL. 
The higher costs of initial bendamustin treatment are in the long-term horizon 
offset by substantial savings of progression costs. There is 100% probability of B-R 
being cost-effective at the selected WTP threshold.
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objeCtives: The inhibition of epidermal growth factor receptor (EGFR) signaling 
pathway by innovative therapeutics presents promising upshots in oncology. Our 
study aims to quantify first-line treatment with afatinib, an irreversible tyrosine 
kinase inhibitor, compared to pemetrexed+cisplatin (pem+cis), for patients with met-
astatic lung adenocarcinoma harboring common EGFR mutations (DEL19 or L858R) in 
the Netherlands. Methods: An area under the curve partitioned survival model, con-
structed to quantify lifetime consequences of therapy with afatinib versus pem+cis, 
was amended to the Netherlands. The updated (2014) LUX-Lung 3 trial results and 
data from public sources were used to populate the model. Study outcomes were 
expressed in quality-adjusted life years (QALY), incremental cost-utility ratios (ICUR) 
and net monetary benefits (NMB). The analyses were conducted from health care and 
societal perspectives. Uncertainty assessment was performed using one-way and 
probabilistic sensitivity analyses (PSA). Results: Metastatic lung adenocarcinoma 
patients with common EGFR mutations (89%) had higher overall survival when treated 
with afatinib compared to pem+cis (HR: 0.78, p= 0.10). The corresponding base-case 
ICUR was < € 20,000/QALY gained. For the subgroup of patients harboring DEL19 muta-
tions (49%), treatment with afatinib resulted in cost-savings. Although NMB calcula-
tions were favorable for the genotype-directed therapy, inclusion of the entire patient 
population (all EGFR mutations) resulted in higher incremental costs. PSA results of 
lung adenocarcinoma patients with common EGFR mutations showed that afatinib 
is > 95% cost-effective compared to pem+cis at a € 80,000 threshold. ConClusions: 
This study shows that genotype-directed therapy with afatinib improved survival in 
metastatic lung adenocarcinoma and translated itself as value-for-money, particu-
larly for the DEL19 subgroup, in the Netherlands. Further research is encouraged to 
compare afatinib with reversible EGFR inhibitors in this setting.
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objeCtives: To assess the cost–utility of erythropoiesis-stimulating agents (ESAs) 
in conjunction with red blood cell transfusions (RBCTs) in patients with cancer-
treatment induced anaemia (CIA). Methods: A cost–utility analysis from an NHS 
and personal social services perspective was conducted by developing an ad hoc 
economic model. A lifetime time horizon was used and outcomes were discounted 
at 3.5% per annum. All ESAs were assumed to have the same clinical effective-
ness. Haemoglobin (Hb) levels were assumed to drive health-related quality of life 
(HRQoL), with haemoglobin linearly mapped to utility. This was used to calculate 
lower than that with Herceptin-IV in the management of patients with HER2+ EBC 
and MBC. Hence, the substitution of Herceptin-IV with Herceptin-SC can produce 
valuable savings for the Greek health care system, especially in the current eco-
nomic environment where hospitals’ pharmaceutical budget has significantly been 
reduced.
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objeCtives: Due to increasing costs in cancer management, there is a crescent 
need to rationally allocate resources in health care systems. Recently, a head-to-
head phase III study (CALGB80405) showed no significant difference in OS and PFS 
for first line (1L) mCRC in KRAS wild-type (wt) patients amongst bevacizumab (Bev) 
and cetuximab (Cet) – the most commonly used biologics in this setting. Since 
benefit of both drugs is comparable, the aim of the study was comparing treatment 
costs of Bev vs. Cet in 1L KRAS wt mCRC. Methods: A cost-minimization analysis 
was conducted under payer perspective in Brazilian Supplementary Healthcare 
System. Backbone chemotherapy regimens (mFOLFOX6 and FOLFIRI) were based 
on CALGB80405 trial. Direct medical costs regarding drug acquisition, material and 
procedures/service fees were included. Adverse events management costs were 
excluded. The resource usage data was taken from the literature and drug labels. 
Costs were taken from CMED price list and UNIMED reimbursement lists. A uni-
variate sensitivity analysis was conducted varying parameters from ±20% range. 
Results were reported in Brazilian Reais (BRL). Results: The average monthly 
cost per patient was lower with Bev: BRL23’945 (Bev+mFOLFOX6) vs. BRL30’017 
(Cet+mFOLFOX6) – reduction of 20.2% - and BRL23’008 (Bev+FOLFIRI) vs. BRL29’075 
(Cet+FOLFIRI) – reduction of 20.9%. Average monthly cost per patient according to 
mFOLFOX6/FOLFIRI usage proportion reported on CALGB80405 was BRL23’699 (Bev) 
and BRL29’766 (Cet); considering PFS data presented in the trial, the average total 
treatment cost was estimated as BRL256’899 (Bev) and BRL311’060 (Cet). The sensi-
tivity analysis showed that model was more influenced by Cet price, Bev price and 
patient height. ConClusions: Bev is a cost-saving choice for 1L KRAS wt mCRC 
in combination with chemotherapy, potentially achieving around 20% of reduction 
in monthly direct treatment costs compared to Cet, mainly because of Cet higher 
total acquisition costs and weekly administration schedule, resulting in additional 
resource consumption.
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objeCtives: To analyze the economic impact of the incorporation of trastu-
zumab subcutaneous (TSC) in a University Hospital according to real data of our 
patients. Methods: Retrospective cost minimization study that included patients 
diagnosed with breast cancer treated with trastuzumab intravenous (TIV) from 
april 2013 to april 2014. The demographic data of the patients (age and weight) 
and antineoplastic treatments used were obtained from the computer program 
Hospiwin®. An economic model was developed in Excel® data base, based on the 
dose used in previous clinical trials: IV loading dose of 8mg/kg and after 6mg/kg/3 
weeks and SC fixed dose of 600 mg/3 weeks. The time horizon was one year and 
the perspective of medical leadership of the hospital was used. The Spain cost of 
TSC is not aproved yet. Two posibilities was analyzed: The cost of filing 600mg of 
TSC equal to the cost of a 68kg patient with TIV (situation A) and the cost of a 63kg 
patient with TIV (situation B). A sensitivity analisys included the cost of using an 
oncology chair (168€ /treatment) was performed. Results: During the study period 
371 patients were treated for breast cancer. Of these 75 were treated with TIV (20.2%), 
with an average weight of 71.5 kg (SD= 17.1) and a cost of 990,996.88€ /per year. If 
all patients had been treated with TSC: Situation A the total spending would be 
829,965.4€ ; situation B the total spending would be 768,938.5€ . So the savings would 
be 161,031.4€ (19.4%) and 222,058.3€ (28.8%) respectively. If the cost of oncology 
chair (not necessary for the TSC) it´s included, the savings would be 253,549.4€ and 
314,576.3 respectively. ConClusions: In this study we wanted to show how TSC 
saved costs in all of the situations analyzed. The TSC is a therapeutic innovation 
that helps promote the systems health´s sustainability.
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objeCtives: To conduct a pharmacoeconomic analysis of oral drugs, tegafur vs 
capecitabine, for advanced colorectal cancer (CRC) in adult patients. Methods: 
Indirect comparison and network meta-analysis of clinical efficacy and safety of 
tegafur vs capecitabine and tegafur + calcium folinate vs capecitabine were per-
formed. Cost-minimization analysis (CMA) with calculation of cost minimization 
difference was used for economic evaluation of studied drugs. Results: There 
was no statistically significant difference in the full and partial objective tumor 
response between oral tegafur (both in monotherapy or in combination with calcium 
folinate) and capecitabine for advanced CRC treatment in an indirect comparison 
and network meta-analysis. Capecitabine vs tegafur + calcium folinate has less 
3-4th grade stomatitis but there was no difference in the incidence of diarrhea and 
3-4th grade nausea/vomiting. There was no difference in safety between tegafur 
